ImmunOs Therapeutics AG, a biopharmaceutical company developing first-in-class therapeutics for the treatment of cancer and autoimmune diseases based on its unique immune system modulating technology platform, closed a Series C financing round. Proceeds from the Series C will be used to further fund the ongoing clinical trial of ImmunOs’ lead program IOS-1002.
